Tuesday, February 3, 2026

Investment of around €500 million: New state-of-the-art production site planned in Saarlouis

With the planned construction of a new, state-of-the-art production facility in Saarlouis, the company is reaching an important milestone in its long-term growth strategy. The project was officially confirmed during a meeting with the Saarland state government at the State Chancellery. This decision underlines the company’s clear commitment to Germany as a business location and to sustainable industrial development.

Construction of the new production site is scheduled to begin in the second quarter of 2026. For the first construction phase of the facility, the company is planning an investment volume of nearly half a billion euros. Commissioning of the site is planned for 2031.

The approximately 40-hectare industrial site in Saarlouis was acquired at the end of 2024. The decision to locate in the Saarland is based on long-term strategic considerations and compelling location factors. The European Commission has approved state aid of up to €47 million for the extensive construction project. In the long term, up to 2,000 jobs could be created at the site. Recruitment will begin once the structural requirements are in place, and open positions will then be published on the company’s job portal.

The new production facility represents one of the largest single investments in the company’s history and a key component of its sustainable growth path. The objective is to strike the right balance between stability and targeted expansion while further strengthening competitiveness in global markets. As a family-owned company, this investment also reaffirms its long-term commitment to the global pharmaceutical market, including ongoing investments in the United States.

The Saarland state government has also welcomed the decision. Minister-President Anke Rehlinger described the investment as a strong signal for the future of the Saarland. Minister of Economic Affairs Jürgen Barke highlighted the importance of the project for economic diversification, job creation, and the sustainable development of the region’s innovation and industrial landscape.

For more than 75 years, the company has stood for quality, innovation, and responsibility in pharmaceutical manufacturing, contributing to improved quality of life for patients worldwide. To meet growing demand and increasing market requirements, the company continues to invest in its existing sites in Germany, Austria, and the United States. With the new site in Saarlouis, production capacities will now be expanded significantly and with a clear focus on the future.